{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T11:52:39Z","timestamp":1771501959600,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Immunity Inflam &amp;amp; Disease"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Prospective studies examining long\u2010term therapeutic outcomes of the Bictegravir\/Emtricitabine\/Tenofovir Alafenamide (BIC\/FTC\/TAF)\u00a0regimen in human immunodeficiency virus (HIV)\u00a0infection remain limited. This study assessed the actual efficacy and safety of BIC\/FTC\/TAF\u00a0in HIV\u2010infected individuals in southwest China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a single\u2010center, prospective study enrolling ART\u2010na\u00efve (<jats:italic>n<\/jats:italic>\u2009=\u200932) and ART\u2010experienced (<jats:italic>n<\/jats:italic>\u2009=\u2009177) HIV\u2010infected patients administered BIC\/FTC\/TAF\u00a0treatment between March 2022 and August 2022. The data were collected until February 28, 2023. Virological reactions and adverse events to the treatment were recorded, and patient subjective feelings in the form of Electronic Patient Reporting Outcome (ePRO) were collected. The primary endpoint was the rate of patients with HIV viral load &lt;50 copies\/mL at Week 24.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At Week 24, 87.5% and 95.5% of ART\u2010na\u00efve and ART\u2010experienced HIV patients had a viral load &lt;50 copies\/mL, respectively. CD4 cell counts in ART\u2010na\u00efve and ART\u2010experienced patients increased significantly by 163.5 cells\/\u03bcL (<jats:italic>p<\/jats:italic>\u2009=\u2009.002) and 55.0 cells\/\u03bcL (<jats:italic>p<\/jats:italic>\u2009=\u2009.022), respectively. By Week 24, no patients had discontinued the BIC\/FTC\/TAF\u00a0treatment due to adverse events. Based on ePRO data, ART\u2010na\u00efve and ART\u2010experienced patients at Week 24 had stable disease symptom burden, quality of life, and depression level after treatment with BIC\/FTC\/TAF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>BIC\/FTC\/TAF\u00a0reduces the viral load in ART\u2010na\u00efve patients with high viral load as well as ART\u2010experienced patients with residual viremia. The patient's subjective experience was maintained stable after treatment with BIC\/FTC\/TAF.\u00a0This study also revealed a very low incidence for BIC\/FTC\/TAF\u00a0drug\u2010related side effects.<\/jats:p><\/jats:sec>","DOI":"10.1002\/iid3.974","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T12:03:48Z","timestamp":1693224228000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical efficacy, safety, and subjective experience based on ePRO in HIV\u2010infected individuals administered Bictegravir\/Emtricitabine\/Tenofovir Alafenamide in southwest China"],"prefix":"10.1002","volume":"11","author":[{"given":"Linghong","family":"Kong","sequence":"first","affiliation":[{"name":"The Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health Guizhou Medical University Guiyang Guizhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxin","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Infection Guiyang Public Health Clinical Center  Guiyang Guizhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhua","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Infection Guiyang Public Health Clinical Center  Guiyang Guizhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Infection Guiyang Public Health Clinical Center  Guiyang Guizhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Yang","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health Guizhou Medical University Guiyang Guizhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujing","family":"Ma","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health Guizhou Medical University Guiyang Guizhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-5623","authenticated-orcid":false,"given":"Hai","family":"Long","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health Guizhou Medical University Guiyang Guizhou China"},{"name":"Department of Infection Guiyang Public Health Clinical Center  Guiyang Guizhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S207908"},{"key":"e_1_2_11_3_1","first-page":"186","article-title":"Patient\u2010reported outcome: comparison between the domestic and the global application progress","volume":"32","author":"Chengchen L","year":"2015","journal-title":"Chin J Drug Eval"},{"key":"e_1_2_11_4_1","first-page":"909","article-title":"Application of ePRO assessing efficacy in clinical trials of new drugs","volume":"44","author":"Xiaoxian L","year":"2021","journal-title":"Drug Eval\u00a0Res"},{"key":"e_1_2_11_5_1","first-page":"937","article-title":"Chinese guidelines for the prevention and treatment of dyslipidemia in adults (2016 revision)","volume":"31","author":"Junren Z","year":"2016","journal-title":"Chin\u00a0Circ\u00a0J"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00449-8"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-164"},{"key":"e_1_2_11_8_1","first-page":"40","article-title":"Study on reliability and validity of Chinese version of EQ\u20105D\u20105L","volume":"34","author":"Yabin X","year":"2013","journal-title":"Shanghai Med Pharm J"},{"key":"e_1_2_11_9_1","first-page":"149","article-title":"Evaluation of the reliability and validity of PHQ\u20109 in general hospital inpatients","volume":"30","author":"Chen Ran","year":"2017","journal-title":"Sichuan Mental Health"},{"key":"e_1_2_11_10_1","first-page":"110","article-title":"A systematic review of the reliability and validity of the Chinese version of the depression scale","volume":"38","author":"Xiaoyan S","year":"2017","journal-title":"Chin J Epidemiol"},{"key":"e_1_2_11_11_1","first-page":"203","article-title":"Chinese guidelines for diagnosis and treatment of human immunodeficiency virus infection\/acquired immunodeficiency syndrome (2021 edition)","volume":"13","author":"AcquiredImmunodeficiency Syndrome and Hepatitis C Professional Group SoID, ChineseMedical Association Chinese Center for Disease Control and Preventio","year":"2022","journal-title":"Med J Peking Union Med Coll Hosp"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab115"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S331647"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.18683\/germs.2021.1286"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab481"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.37201\/req\/148.2020"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10081823"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.21037\/jlpm.2018.01.10"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa625"},{"key":"e_1_2_11_20_1","first-page":"760","article-title":"Efficacy and associated factors of HAART on AIDS patients","volume":"23","author":"Bin W","year":"2017","journal-title":"Chin J AIDS STD"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00419-5"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2018.04.100"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.2007006"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.36469\/jheor.2021.2435"}],"container-title":["Immunity, Inflammation and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.974","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T11:19:44Z","timestamp":1698664784000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iid3.974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1002\/iid3.974"],"URL":"https:\/\/doi.org\/10.1002\/iid3.974","archive":["Portico"],"relation":{},"ISSN":["2050-4527","2050-4527"],"issn-type":[{"value":"2050-4527","type":"print"},{"value":"2050-4527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"2023-05-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e974"}}